Cointime update: BioNTech has purchased an FDA priority review voucher for $205 million. The voucher allows its holder to expedite regulatory review of a single drug application. The transaction was reported by Bloomberg, which did not specify which product the company intends to use the voucher for.
BioNTech Buys FDA Priority Review Voucher for $205M
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
3h ago
House Democrats Target Trump Inner Circle in First Oversight Requests
3h ago
US Democrats Plan Data Center Power Reform, Operators May Pay $35B More Over 10 Years
4h ago
Democrats to Probe Trump’s $100B Venezuela Oil Deal
5h ago
UBS Global Wealth Management Forecasts S&P 500 at 8,200 by End-2027
6h ago
Tencent Q3 2026 Revenue Rises 8% to RMB 207.3 Billion
6h ago
Onshore yuan closes at 6.6653 per dollar, up 2 pips